1
|
Bayle A, Peyraud F, Belcaid L, Brunet M, Aldea M, Clodion R, Dubos P, Vasseur D, Nicotra C, Geraud A, Sakkal M, Cerbone L, Blanc-Durand F, Mosele F, Romano PM, Camus MN, Soubeyran I, Khalifa E, Alame M, Blouin L, Dinart D, Bellera C, Hollebecque A, Ponce S, Loriot Y, Besse B, Lacroix L, Rouleau E, Barlesi F, Andre F, Italiano A. Liquid versus tissue biopsy for detecting actionable alterations according to ESCAT in patients with advanced cancer: A study from the French National Center for Precision Medicine (PRISM). Ann Oncol 2022; 33:1328-1331. [PMID: 36122799 DOI: 10.1016/j.annonc.2022.08.089] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2022] [Accepted: 08/31/2022] [Indexed: 11/01/2022] Open
Affiliation(s)
- A Bayle
- Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif;; Université Paris Saclay, Université Paris-Sud, Faculté de médicine, Le Kremlin Bicêtre, Paris;; Oncostat U1018, Inserm, Paris-Saclay University, labeled Ligue Contre le Cancer, Villejuif
| | - F Peyraud
- Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif;; Department of Early Phase Trial Unit, Institut Bergonié Comprehensive Cancer Centre, Bordeaux,; University of Bordeaux, Bordeaux, France
| | - L Belcaid
- Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif;; Department of Oncology, Rigshospitalet, The University of Copenhagen, Denmark
| | - M Brunet
- Department of Early Phase Trial Unit, Institut Bergonié Comprehensive Cancer Centre, Bordeaux
| | - M Aldea
- Université Paris Saclay, Université Paris-Sud, Faculté de médicine, Le Kremlin Bicêtre, Paris;; Department of Cancer Medicine, Gustave Roussy
| | - R Clodion
- Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif
| | - P Dubos
- Department of Early Phase Trial Unit, Institut Bergonié Comprehensive Cancer Centre, Bordeaux
| | - D Vasseur
- Department of Medical Biology and Pathology, Gustave Roussy, Villejuif
| | - C Nicotra
- Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif
| | - A Geraud
- Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif
| | - M Sakkal
- Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif
| | - L Cerbone
- Department of Cancer Medicine, Gustave Roussy
| | | | - F Mosele
- Department of Cancer Medicine, Gustave Roussy
| | - P Martin Romano
- Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif
| | - M Ngo Camus
- Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif
| | - I Soubeyran
- Department of Medical Biology and Pathology, Institut Bergonié Comprehensive Cancer Centre
| | - E Khalifa
- Department of Medical Biology and Pathology, Institut Bergonié Comprehensive Cancer Centre
| | - M Alame
- Department of Medical Biology and Pathology, Institut Bergonié Comprehensive Cancer Centre
| | - L Blouin
- Department of Medical Biology and Pathology, Institut Bergonié Comprehensive Cancer Centre
| | - D Dinart
- Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene team; Inserm CIC1401, Clinical and Epidemiological Research Unit,Institut Bergonié, Comprehensive Cancer Center, Bordeaux
| | - C Bellera
- Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene team; Inserm CIC1401, Clinical and Epidemiological Research Unit,Institut Bergonié, Comprehensive Cancer Center, Bordeaux
| | - A Hollebecque
- Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif
| | - S Ponce
- Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif
| | - Y Loriot
- Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif
| | - B Besse
- Université Paris Saclay, Université Paris-Sud, Faculté de médicine, Le Kremlin Bicêtre, Paris;; Department of Cancer Medicine, Gustave Roussy
| | - Ludovic Lacroix
- Department of Medical Biology and Pathology, Gustave Roussy, Villejuif
| | - E Rouleau
- Department of Medical Biology and Pathology, Gustave Roussy, Villejuif
| | - F Barlesi
- Department of Cancer Medicine, Gustave Roussy;; Aix Marseille University, CNRS, INSERM, CRCM, Marseille
| | - F Andre
- Université Paris Saclay, Université Paris-Sud, Faculté de médicine, Le Kremlin Bicêtre, Paris;; Department of Cancer Medicine, Gustave Roussy
| | - A Italiano
- Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif;; Department of Early Phase Trial Unit, Institut Bergonié Comprehensive Cancer Centre, Bordeaux,; University of Bordeaux, Bordeaux, France;.
| |
Collapse
|
2
|
Walker PM, Hirayama Y, Lane GJ, Watanabe H, Dracoulis GD, Ahmed M, Brunet M, Hashimoto T, Ishizawa S, Kondev FG, Litvinov YA, Miyatake H, Moon JY, Mukai M, Niwase T, Park JH, Podolyák Z, Rosenbusch M, Schury P, Wada M, Watanabe XY, Liang WY, Xu FR. Properties of ^{187}Ta Revealed through Isomeric Decay. Phys Rev Lett 2020; 125:192505. [PMID: 33216598 DOI: 10.1103/physrevlett.125.192505] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/24/2020] [Accepted: 10/13/2020] [Indexed: 06/11/2023]
Abstract
Mass-separated ^{187}Ta_{114} in a high-spin isomeric state has been produced for the first time by multinucleon transfer reactions, employing an argon gas-stopping cell and laser ionization. Internal γ rays revealed a T_{1/2}=7.3±0.9 s isomer at 1778±1 keV, which decays through a rotational band with perturbations associated with the approach to a prolate-oblate shape transition. Model calculations show less influence from triaxiality compared to heavier elements in the same mass region. The isomer-decay reduced E2 hindrance factor f_{ν}=27±1 supports the interpretation that axial symmetry is approximately conserved.
Collapse
Affiliation(s)
- P M Walker
- Department of Physics, University of Surrey, Guildford, GU2 7XH, United Kingdom
| | - Y Hirayama
- Wako Nuclear Science Center (WNSC), Institute of Particle and Nuclear Studies (IPNS), High Energy Accelerator Research Organization (KEK), Wako, Saitama 351-0198, Japan
| | - G J Lane
- Department of Nuclear Physics, RSPhys, Australian National University, Canberra, Australian Capital Territory 2601, Australia
| | - H Watanabe
- School of Physics, and International Research Center for Nuclei and Particles in Cosmos, Beihang University, Beijing 100191, China
- Nishina Center for Accelerator-Based Science, RIKEN, Wako, Saitama 351-0198, Japan
| | - G D Dracoulis
- Department of Nuclear Physics, RSPhys, Australian National University, Canberra, Australian Capital Territory 2601, Australia
| | - M Ahmed
- Wako Nuclear Science Center (WNSC), Institute of Particle and Nuclear Studies (IPNS), High Energy Accelerator Research Organization (KEK), Wako, Saitama 351-0198, Japan
- University of Tsukuba, Tsukuba, Ibaraki 305-0006, Japan
| | - M Brunet
- Department of Physics, University of Surrey, Guildford, GU2 7XH, United Kingdom
| | - T Hashimoto
- Rare Isotope Science Project, Institute for Basic Science (IBS), Daejeon 305-811, Republic of Korea
| | - S Ishizawa
- Wako Nuclear Science Center (WNSC), Institute of Particle and Nuclear Studies (IPNS), High Energy Accelerator Research Organization (KEK), Wako, Saitama 351-0198, Japan
- Nishina Center for Accelerator-Based Science, RIKEN, Wako, Saitama 351-0198, Japan
- Graduate School of Science and Engineering, Yamagata University, Yamagata 992-8510, Japan
| | - F G Kondev
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - Yu A Litvinov
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - H Miyatake
- Wako Nuclear Science Center (WNSC), Institute of Particle and Nuclear Studies (IPNS), High Energy Accelerator Research Organization (KEK), Wako, Saitama 351-0198, Japan
| | - J Y Moon
- Rare Isotope Science Project, Institute for Basic Science (IBS), Daejeon 305-811, Republic of Korea
| | - M Mukai
- Wako Nuclear Science Center (WNSC), Institute of Particle and Nuclear Studies (IPNS), High Energy Accelerator Research Organization (KEK), Wako, Saitama 351-0198, Japan
- Nishina Center for Accelerator-Based Science, RIKEN, Wako, Saitama 351-0198, Japan
- University of Tsukuba, Tsukuba, Ibaraki 305-0006, Japan
| | - T Niwase
- Wako Nuclear Science Center (WNSC), Institute of Particle and Nuclear Studies (IPNS), High Energy Accelerator Research Organization (KEK), Wako, Saitama 351-0198, Japan
- Nishina Center for Accelerator-Based Science, RIKEN, Wako, Saitama 351-0198, Japan
- Department of Physics, Kyushu University, Nishi-ku, Fukuoka 819-0395, Japan
| | - J H Park
- Rare Isotope Science Project, Institute for Basic Science (IBS), Daejeon 305-811, Republic of Korea
| | - Zs Podolyák
- Department of Physics, University of Surrey, Guildford, GU2 7XH, United Kingdom
| | - M Rosenbusch
- Wako Nuclear Science Center (WNSC), Institute of Particle and Nuclear Studies (IPNS), High Energy Accelerator Research Organization (KEK), Wako, Saitama 351-0198, Japan
| | - P Schury
- Wako Nuclear Science Center (WNSC), Institute of Particle and Nuclear Studies (IPNS), High Energy Accelerator Research Organization (KEK), Wako, Saitama 351-0198, Japan
| | - M Wada
- Wako Nuclear Science Center (WNSC), Institute of Particle and Nuclear Studies (IPNS), High Energy Accelerator Research Organization (KEK), Wako, Saitama 351-0198, Japan
- University of Tsukuba, Tsukuba, Ibaraki 305-0006, Japan
| | - X Y Watanabe
- Wako Nuclear Science Center (WNSC), Institute of Particle and Nuclear Studies (IPNS), High Energy Accelerator Research Organization (KEK), Wako, Saitama 351-0198, Japan
| | - W Y Liang
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - F R Xu
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| |
Collapse
|
3
|
Carroll RJ, Podolyák Z, Berry T, Grawe H, Alexander T, Andreyev AN, Ansari S, Borge MJG, Brunet M, Creswell JR, Fraile LM, Fahlander C, Fynbo HOU, Gamba ER, Gelletly W, Gerst RB, Górska M, Gredley A, Greenlees PT, Harkness-Brennan LJ, Huyse M, Judge SM, Judson DS, Konki J, Kurcewicz J, Kuti I, Lalkovski S, Lazarus IH, Lică R, Lund M, Madurga M, Marginean N, Marginean R, Marroquin I, Mihai C, Mihai RE, Nácher E, Negret A, Nita C, Pascu S, Page RD, Patel Z, Perea A, Phrompao J, Piersa M, Pucknell V, Rahkila P, Rapisarda E, Regan PH, Rotaru F, Rudigier M, Shand CM, Shearman R, Stegemann S, Stora T, Sotty C, Tengblad O, Van Duppen P, Vedia V, Wadsworth R, Walker PM, Warr N, Wearing F, De Witte H. Competition between Allowed and First-Forbidden β Decay: The Case of ^{208}Hg→^{208}Tl. Phys Rev Lett 2020; 125:192501. [PMID: 33216605 DOI: 10.1103/physrevlett.125.192501] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/07/2020] [Revised: 09/21/2020] [Accepted: 10/07/2020] [Indexed: 06/11/2023]
Abstract
The β decay of ^{208}Hg into the one-proton hole, one neutron-particle _{81}^{208}Tl_{127} nucleus was investigated at CERN-ISOLDE. Shell-model calculations describe well the level scheme deduced, validating the proton-neutron interactions used, with implications for the whole of the N>126, Z<82 quadrant of neutron-rich nuclei. While both negative and positive parity states with spin 0 and 1 are expected within the Q_{β} window, only three negative parity states are populated directly in the β decay. The data provide a unique test of the competition between allowed Gamow-Teller and Fermi, and first-forbidden β decays, essential for the understanding of the nucleosynthesis of heavy nuclei in the rapid neutron capture process. Furthermore, the observation of the parity changing 0^{+}→0^{-}β decay where the daughter state is core excited is unique, and can provide information on mesonic corrections of effective operators.
Collapse
Affiliation(s)
- R J Carroll
- Department of Physics, University of Surrey, Guildford GU2 7XH, United Kingdom
| | - Zs Podolyák
- Department of Physics, University of Surrey, Guildford GU2 7XH, United Kingdom
- ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung, Planckstrasse 1, 64291 Darmstadt, Germany
| | - T Berry
- Department of Physics, University of Surrey, Guildford GU2 7XH, United Kingdom
| | - H Grawe
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstrasse 1, 64291 Darmstadt, Germany
| | - T Alexander
- Department of Physics, University of Surrey, Guildford GU2 7XH, United Kingdom
| | - A N Andreyev
- University of York, Dept Phys, North Yorkshire YO10 5DD, United Kingdom
- Advanced Science Research Center, Japan Atomic Energy Agency, Tokai-mura, Ibaraki 319-1195, Japan
| | - S Ansari
- Institut für Kernphysik der Universität zu Köln, Zülpicher Str. 77, 50937 Köln, Germany
| | - M J G Borge
- CERN, Physics Department, 1211 Geneva 23, Switzerland
| | - M Brunet
- Department of Physics, University of Surrey, Guildford GU2 7XH, United Kingdom
| | - J R Creswell
- Department of Physics, Oliver Lodge Laboratory, University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - L M Fraile
- Grupo de Física Nuclear & IPARCOS, Universidad Complutense de Madrid, CEI Moncloa, E-28040 Madrid, Spain
| | - C Fahlander
- Department of Physics, Lund University, S-22100 Lund, Sweden
| | - H O U Fynbo
- Department of Physics and Astronomy, Aarhus University, DK-8000 Aarhus, Denmark
| | - E R Gamba
- University of Brighton, Brighton BN2 4GJ, United Kingdom
| | - W Gelletly
- Department of Physics, University of Surrey, Guildford GU2 7XH, United Kingdom
| | - R-B Gerst
- Institut für Kernphysik der Universität zu Köln, Zülpicher Str. 77, 50937 Köln, Germany
| | - M Górska
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstrasse 1, 64291 Darmstadt, Germany
| | - A Gredley
- Department of Physics, Oliver Lodge Laboratory, University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - P T Greenlees
- University of Jyvaskyla, Department of Physics, University of Jyvaskyla, P.O. Box 35, FI-40014 Jyvaskyla, Finland
- Helsinki Institute of Physics, University of Helsinki, P.O. Box 64, FI-00014 Helsinki, Finland
| | - L J Harkness-Brennan
- Department of Physics, Oliver Lodge Laboratory, University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - M Huyse
- KU Leuven, Instituut voor Kern- en Stralingsfysica, Celestijnenlaan 200D, 3001 Leuven, Belgium
| | - S M Judge
- National Physical Laboratory, Teddington, Middlesex TW11 0LW, United Kingdom
| | - D S Judson
- Department of Physics, Oliver Lodge Laboratory, University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - J Konki
- University of Jyvaskyla, Department of Physics, University of Jyvaskyla, P.O. Box 35, FI-40014 Jyvaskyla, Finland
- Helsinki Institute of Physics, University of Helsinki, P.O. Box 64, FI-00014 Helsinki, Finland
| | - J Kurcewicz
- CERN, Physics Department, 1211 Geneva 23, Switzerland
| | - I Kuti
- Institute of Nuclear Research of the Hungarian Academy of Sciences, 4026 Debrecen, Hungary
| | - S Lalkovski
- Department of Physics, University of Surrey, Guildford GU2 7XH, United Kingdom
| | - I H Lazarus
- STFC, Daresbury Laboratory, Warrington WA4 4AD, United Kingdom
| | - R Lică
- CERN, Physics Department, 1211 Geneva 23, Switzerland
- Horea Hulubei National Institute for Physics and Nuclear Engineering, RO-077125 Bucharest, Romania
| | - M Lund
- Department of Physics and Astronomy, Aarhus University, DK-8000 Aarhus, Denmark
| | - M Madurga
- CERN, Physics Department, 1211 Geneva 23, Switzerland
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37996, USA
| | - N Marginean
- Horea Hulubei National Institute for Physics and Nuclear Engineering, RO-077125 Bucharest, Romania
| | - R Marginean
- Horea Hulubei National Institute for Physics and Nuclear Engineering, RO-077125 Bucharest, Romania
| | - I Marroquin
- Instituto de Estructura de la Materia, CSIC, Serrano 113 bis, E-28006 Madrid, Spain
| | - C Mihai
- Horea Hulubei National Institute for Physics and Nuclear Engineering, RO-077125 Bucharest, Romania
| | - R E Mihai
- Horea Hulubei National Institute for Physics and Nuclear Engineering, RO-077125 Bucharest, Romania
| | - E Nácher
- Instituto de Estructura de la Materia, CSIC, Serrano 113 bis, E-28006 Madrid, Spain
| | - A Negret
- Horea Hulubei National Institute for Physics and Nuclear Engineering, RO-077125 Bucharest, Romania
| | - C Nita
- University of Brighton, Brighton BN2 4GJ, United Kingdom
- Horea Hulubei National Institute for Physics and Nuclear Engineering, RO-077125 Bucharest, Romania
| | - S Pascu
- Horea Hulubei National Institute for Physics and Nuclear Engineering, RO-077125 Bucharest, Romania
| | - R D Page
- Department of Physics, Oliver Lodge Laboratory, University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - Z Patel
- Department of Physics, University of Surrey, Guildford GU2 7XH, United Kingdom
| | - A Perea
- Instituto de Estructura de la Materia, CSIC, Serrano 113 bis, E-28006 Madrid, Spain
| | - J Phrompao
- Department of Physics and Materials Science, Chiang Mai University, 50200 Chiang Mai, Thailand
| | - M Piersa
- Faculty of Physics, University of Warsaw, PL 02-093 Warsaw, Poland
| | - V Pucknell
- STFC, Daresbury Laboratory, Warrington WA4 4AD, United Kingdom
| | - P Rahkila
- University of Jyvaskyla, Department of Physics, University of Jyvaskyla, P.O. Box 35, FI-40014 Jyvaskyla, Finland
- Helsinki Institute of Physics, University of Helsinki, P.O. Box 64, FI-00014 Helsinki, Finland
| | - E Rapisarda
- CERN, Physics Department, 1211 Geneva 23, Switzerland
| | - P H Regan
- Department of Physics, University of Surrey, Guildford GU2 7XH, United Kingdom
- National Physical Laboratory, Teddington, Middlesex TW11 0LW, United Kingdom
| | - F Rotaru
- Horea Hulubei National Institute for Physics and Nuclear Engineering, RO-077125 Bucharest, Romania
| | - M Rudigier
- Department of Physics, University of Surrey, Guildford GU2 7XH, United Kingdom
| | - C M Shand
- Department of Physics, University of Surrey, Guildford GU2 7XH, United Kingdom
| | - R Shearman
- Department of Physics, University of Surrey, Guildford GU2 7XH, United Kingdom
- National Physical Laboratory, Teddington, Middlesex TW11 0LW, United Kingdom
| | - S Stegemann
- Institut für Kernphysik der Universität zu Köln, Zülpicher Str. 77, 50937 Köln, Germany
| | - T Stora
- CERN, Physics Department, 1211 Geneva 23, Switzerland
| | - Ch Sotty
- KU Leuven, Instituut voor Kern- en Stralingsfysica, Celestijnenlaan 200D, 3001 Leuven, Belgium
- Horea Hulubei National Institute for Physics and Nuclear Engineering, RO-077125 Bucharest, Romania
| | - O Tengblad
- Instituto de Estructura de la Materia, CSIC, Serrano 113 bis, E-28006 Madrid, Spain
| | - P Van Duppen
- KU Leuven, Instituut voor Kern- en Stralingsfysica, Celestijnenlaan 200D, 3001 Leuven, Belgium
| | - V Vedia
- Grupo de Física Nuclear & IPARCOS, Universidad Complutense de Madrid, CEI Moncloa, E-28040 Madrid, Spain
| | - R Wadsworth
- University of York, Dept Phys, North Yorkshire YO10 5DD, United Kingdom
| | - P M Walker
- Department of Physics, University of Surrey, Guildford GU2 7XH, United Kingdom
| | - N Warr
- Institut für Kernphysik der Universität zu Köln, Zülpicher Str. 77, 50937 Köln, Germany
| | - F Wearing
- Department of Physics, Oliver Lodge Laboratory, University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - H De Witte
- KU Leuven, Instituut voor Kern- en Stralingsfysica, Celestijnenlaan 200D, 3001 Leuven, Belgium
| |
Collapse
|
4
|
Larrieu D, Brunet M, Vargas C, Hanoun N, Ligat L, Dagnon L, Lulka H, Pommier RM, Selves J, Jády BE, Bartholin L, Cordelier P, Dufresne M, Torrisani J. The E3 ubiquitin ligase TRIP12 participates in cell cycle progression and chromosome stability. Sci Rep 2020; 10:789. [PMID: 31964993 PMCID: PMC6972862 DOI: 10.1038/s41598-020-57762-9] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2019] [Accepted: 01/03/2020] [Indexed: 12/29/2022] Open
Abstract
Several studies have linked the E3 ubiquitin ligase TRIP12 (Thyroid hormone Receptor Interacting Protein 12) to the cell cycle. However, the regulation and the implication of this protein during the cell cycle are largely unknown. In this study, we show that TRIP12 expression is regulated during the cell cycle, which correlates with its nuclear localization. We identify an euchromatin-binding function of TRIP12 mediated by a N-terminal intrinsically disordered region. We demonstrate the functional implication of TRIP12 in the mitotic entry by controlling the duration of DNA replication that is independent from its catalytic activity. We also show the requirement of TRIP12 in the mitotic progression and chromosome stability. Altogether, our findings show that TRIP12 is as a new chromatin-associated protein with several implications in the cell cycle progression and in the maintenance of genome integrity.
Collapse
Affiliation(s)
- D Larrieu
- Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - M Brunet
- Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - C Vargas
- Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - N Hanoun
- Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - L Ligat
- Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - L Dagnon
- Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - H Lulka
- Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - R M Pommier
- Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de recherche en cancérologie de Lyon, Lyon, 69008, France
| | - J Selves
- Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - B E Jády
- Laboratoire de Biologie Moléculaire Eucaryote du CNRS, UMR5099, Centre de Biologie Intégrative, Université Toulouse III-Paul Sabatier, Toulouse, Cedex 9, France
| | - L Bartholin
- Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de recherche en cancérologie de Lyon, Lyon, 69008, France
| | - P Cordelier
- Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - M Dufresne
- Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - J Torrisani
- Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France.
| |
Collapse
|
5
|
Delhumau S, Le Roux G, Meyer G, Touré A, Brunet M, Deguigne M. Surdosage en valpromide : comment interpréter le dosage plasmatique de l’acide valproïque ? Toxicologie Analytique et Clinique 2018. [DOI: 10.1016/j.toxac.2018.07.109] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
6
|
Brunet M, Aureau D, Guillemot F, Etcheberry A, Ozanam F, Gouget-Laemmel AC. The critical role of wavelength in the UV-activated grafting of 1-alkene onto silicon and silicon nitride Si xN 4 surfaces. Chem Commun (Camb) 2018; 54:7167-7170. [DOI: 10.1039/c8cc03207f] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The wavelength used during photochemical grafting of alkene onto silicon related surfaces influences molecular surface coverage.
Collapse
Affiliation(s)
- M. Brunet
- Physique de la Matière Condensée
- Ecole Polytechnlque
- CNRS
- Université Paris Saclay
- 91128 Palaiseau
| | - D. Aureau
- Institut Lavoisier de Versailles
- UMR 8180 UVSQ-CNRS
- Université Paris Saclay
- Versailles
- France
| | | | - A. Etcheberry
- Institut Lavoisier de Versailles
- UMR 8180 UVSQ-CNRS
- Université Paris Saclay
- Versailles
- France
| | - F. Ozanam
- Physique de la Matière Condensée
- Ecole Polytechnlque
- CNRS
- Université Paris Saclay
- 91128 Palaiseau
| | - A. C. Gouget-Laemmel
- Physique de la Matière Condensée
- Ecole Polytechnlque
- CNRS
- Université Paris Saclay
- 91128 Palaiseau
| |
Collapse
|
7
|
Pericàs JM, García-de-la-Mària C, Brunet M, Armero Y, García-González J, Casals G, Almela M, Quintana E, Falces C, Ninot S, Fuster D, Llopis J, Marco F, Moreno A, Miró JM. Early in vitro development of daptomycin non-susceptibility in high-level aminoglycoside-resistant Enterococcus faecalis predicts the efficacy of the combination of high-dose daptomycin plus ampicillin in an in vivo model of experimental endocarditis. J Antimicrob Chemother 2017; 72:1714-1722. [PMID: 28204495 DOI: 10.1093/jac/dkx016] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2016] [Accepted: 01/09/2017] [Indexed: 11/14/2022] Open
Abstract
Background Previous studies showed development of daptomycin non-susceptibility (DNS: MIC >4 mg/L) in Enterococcus faecalis infections. However, no studies have assessed the efficacy of the combination of daptomycin/ampicillin against E. faecalis strains developing DNS in the experimental endocarditis (EE) model. Objectives To assess the in vitro and in vivo efficacy of daptomycin at 10 mg/kg/day, daptomycin/ampicillin and ampicillin/ceftriaxone against two high-level aminoglycoside-resistant E. faecalis strains, one developing DNS after in vitro exposure to daptomycin and another that did not (DS). Methods Subculture of 82 E. faecalis strains from patients with endocarditis with daptomycin MICs, time-kill and in vivo experiments using the EE model. Results 33% of the strains (27 of 82) displayed DNS after subculture with daptomycin. Daptomycin MIC rose from 0.5-2 to 8-16 mg/L. In time-kill experiments, when using a high inoculum (10 8 cfu/mL), daptomycin/ampicillin was synergistic for one-third of DS strains and none of DNS strains, while ampicillin/ceftriaxone retained synergy in all cases. In the EE model, daptomycin did not significantly reduce cfu/g from vegetations compared with control against either strain, while daptomycin/ampicillin reduced significantly more cfu/g than daptomycin against the DS strain, but not against the DNS strain [2.9 (2.0-4.1) versus 6.1 (4.5-8.0); P = 0.002]. Ampicillin/ceftriaxone was synergistic and bactericidal against both strains, displaying the same activity as daptomycin/ampicillin against the DS strain. Conclusions Performance of an Etest for daptomycin MIC after subculture with daptomycin inhibitory doses on strains of high-level aminoglycoside-resistant E. faecalis endocarditis may be an easy test to predict the in vivo efficacy of daptomycin/ampicillin.
Collapse
Affiliation(s)
- J M Pericàs
- Infectious Diseases Service, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques Pi i Sunyer (IDIBAPS), University of Barcelona, Spain
| | - C García-de-la-Mària
- Infectious Diseases Service, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques Pi i Sunyer (IDIBAPS), University of Barcelona, Spain
| | - M Brunet
- Pharmacology and Toxicology Unit, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques Pi i Sunyer (IDIBAPS), University of Barcelona, Spain
| | - Y Armero
- Infectious Diseases Service, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques Pi i Sunyer (IDIBAPS), University of Barcelona, Spain
| | - J García-González
- Infectious Diseases Service, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques Pi i Sunyer (IDIBAPS), University of Barcelona, Spain
| | - G Casals
- Pharmacology and Toxicology Unit, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques Pi i Sunyer (IDIBAPS), University of Barcelona, Spain
| | - M Almela
- Microbiology Service, Center Diagnostic Biomedical (CDB), Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques Pi i Sunyer (IDIBAPS), University of Barcelona, Spain
| | - E Quintana
- Cardiac Surgery Service, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques Pi i Sunyer (IDIBAPS), University of Barcelona, Spain
| | - C Falces
- Cardiology Department, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques Pi i Sunyer (IDIBAPS), University of Barcelona, Spain
| | - S Ninot
- Cardiac Surgery Service, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques Pi i Sunyer (IDIBAPS), University of Barcelona, Spain
| | - D Fuster
- Nuclear Medicine Department, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques Pi i Sunyer (IDIBAPS), University of Barcelona, Spain
| | - J Llopis
- Department of Statistics, Faculty of Biology, University of Barcelona, Spain
| | - F Marco
- Microbiology Service, Center Diagnostic Biomedical (CDB), Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques Pi i Sunyer (IDIBAPS), University of Barcelona, Spain.,ISGlobal, Barcelona Ctr. Int, Health Res. (CRESIB), Hospital Clinic of Barcelona, University of Barcelona, Spain
| | - A Moreno
- Infectious Diseases Service, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques Pi i Sunyer (IDIBAPS), University of Barcelona, Spain
| | - J M Miró
- Infectious Diseases Service, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques Pi i Sunyer (IDIBAPS), University of Barcelona, Spain
| | | |
Collapse
|
8
|
Affiliation(s)
- B. Laponche
- Centre D’Études Nucléaires de Saclay B. P. 2, 91 Gif-sur-Yvette, France
| | - M. Brunet
- Centre D’Études Nucléaires de Saclay B. P. 2, 91 Gif-sur-Yvette, France
| | - Y. Bouedo
- Centre D’Études Nucléaires de Saclay B. P. 2, 91 Gif-sur-Yvette, France
| |
Collapse
|
9
|
Le Roux G, Brunet M, Leger M, Touré A, Billat PA, Lerolle N, Boels D. Intoxication par le baclofène : l’épuration extrarénale est-elle efficace chez le patient normorénal ? Toxicologie Analytique et Clinique 2017. [DOI: 10.1016/j.toxac.2017.03.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
10
|
Brunet M, Williams C. Défauts dans les smectiques C chiraux. I. — Réseau périodique de paires de lignes provoqué par une orientation planaire. ACTA ACUST UNITED AC 2017. [DOI: 10.1051/anphys/197803030237] [Citation(s) in RCA: 47] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
11
|
Alfon J, Vidal L, Gaba L, Victoria I, Gil M, Laquente B, Brunet M, Colom H, Ramis J, Perez-Montoyo H, Cortal M, Gomez-Ferreria M, Muñoz P, Erazo T, Lizcano J, Domenech C, Gascon P. Determination of recommended phase II dose of ABTL0812, a novel regulator of Akt/mTOR axis, by pharmacokinetic-pharmacodynamic modelling. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw368.21] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
12
|
Brunet M, Lelièvre B, Jegou F, Le Roux G, Abbara C, Turcant A, Bretaudeau Deguigne M. Enzalutamide (Xtandi®) et interférence analytique lors du dosage de la digoxinémie. Toxicologie Analytique et Clinique 2016. [DOI: 10.1016/j.toxac.2016.05.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
13
|
De Pralormo S, Marquis A, Brunet M, Bretaudeau Deguigne M. Risques liés à l’ingestion de pains de savon : à propos de 553 cas. Toxicologie Analytique et Clinique 2016. [DOI: 10.1016/j.toxac.2016.05.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
14
|
Millán O, Jiménez O, Fortuna V, Barceló J, Brunet M. Role of FK778 Alone or in Combination with Tacrolimus or mTOR Inhibitors as an Immunomodulator of Immunofunctions: In Vitro Evaluation of T Cell Proliferation and the Expression of Lymphocyte Surface Antigens. Int J Immunopathol Pharmacol 2016. [DOI: 10.1177/039463200601900209] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
We evaluated the in vitro capacity of FK778, alone or in combination with other immunosuppressive drugs: Tacrolimus (TRL); Sirolimus (SRL), Everolimus (EVL), to inhibit clonal expansion of T-lymphocytes and expression of lymphocyte-activation surface antigens; secondly, we compared the immunosuppressive potential of FK778 combined with TRL, SRL and EVL with the same combinations using Mycophenolic acid (MPA) as antimetabolite. Lymphocyte proliferation was assessed by 3H-Thymidine incorporation, in whole blood cultures stimulated with ConA. The effect of FK778 on alloresponse was evaluated by MLC and the expression of lymphocyte surface antigens by cytometry. FK778, TRL, SRL and EVL showed a high in vitro capacity to inhibit lymphocyte proliferation in a concentration-dependent way. Combinations of FK778 with TRL, SRL, or EVL presented an additive effect, especially FK778+TRL. Similar inhibition capacity of the clonal expansion was observed, when FK778 was combined with TRL, SRL or EVL, respecting the same combinations but using MPA instead of FK778. In addition, FK778 inhibited the expression of lymphocyte surface antigens involved in activation, co-stimulatory and apoptosis signals. In conclusion, FK778 inhibits the proliferative response induced by mitogeneic and allogeneic stimuli and the expression of surface antigens. Combinations of FK778 with TRL or mTOR inhibitors presented an additive effect and their action on T cell proliferation was similar to that of combinations with MPA. Since FK778, TRL and mTOR inhibitors present different action mechanisms and involve different cellular targets, these combinations may help prevent episodes of allorejection in organ transplants. FK778 and mTOR inhibitors may represent an alternative treatment for patients with renal failure.
Collapse
Affiliation(s)
| | | | | | - J.J. Barceló
- Servicio de Inmunología, IDIBAPS, Hospital Clínic, Universitat de Barcelona, Spain
| | | |
Collapse
|
15
|
Crespo G, Gambato M, Millán O, Casals G, Ruiz P, Londoño MC, Mira A, Forns X, Brunet M, Jiménez W, Navasa M. Early non-invasive selection of patients at high risk of severe hepatitis C recurrence after liver transplantation. Transpl Infect Dis 2016; 18:471-9. [PMID: 26992003 DOI: 10.1111/tid.12526] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2015] [Revised: 12/04/2015] [Accepted: 01/20/2016] [Indexed: 01/10/2023]
Abstract
BACKGROUND The early identification of patients at high risk of severe post liver transplant hepatitis C recurrence is relevant, as these patients may be treated using interferon (IFN)-free regimens. METHODS In a retrospective study with prospectively collected data, we investigated whether the use of several non-invasive methods (fibrosis 4 index [FIB-4], AST-to-platelets ratio index [APRI], enhanced liver fibrosis test [ELF], IFN-γ-inducible protein 10 [IP-10], and transient elastography by Fibroscan) and their combinations 6 months after transplantation could identify those recipients at higher risk of severe recurrence, defined by the presence of significant fibrosis (F ≥2) and/or portal hypertension (hepatic venous pressure gradient ≥6 mmHg) 12 months after transplant. Seventy-two hepatitis C virus (HCV)-infected liver transplant patients and 10 recipients in whom HCV was eradicated before transplantation were included in the study. RESULTS The levels of all biomarkers were significantly higher in HCV-infected recipients than in controls. Among HCV recipients, levels of biomarkers were significantly higher in patients with severe recurrence. Although there were no statistically significant differences between biomarkers, APRI, ELF, and FIB-4 obtained the highest area under the ROC curve values. The combination of serum biomarkers with Fibroscan increased the negative and positive predictive values, although diagnostic accuracy of individual tests was not significantly improved. CONCLUSIONS Patients at higher risk of severe HCV recurrence can be identified early, 6 months after transplantation, using readily available non-invasive methods.
Collapse
Affiliation(s)
- G Crespo
- Liver Unit, Hospital Clinic, IDIBAPS and CIBERehd, University of Barcelona, Barcelona, Spain
| | - M Gambato
- Liver Unit, Hospital Clinic, IDIBAPS and CIBERehd, University of Barcelona, Barcelona, Spain
| | - O Millán
- Department of Biochemistry and Molecular Genetics, Hospital Clinic, IDIBAPS and CIBERehd, University of Barcelona, Barcelona, Spain
| | - G Casals
- Department of Biochemistry and Molecular Genetics, Hospital Clinic, IDIBAPS and CIBERehd, University of Barcelona, Barcelona, Spain
| | - P Ruiz
- Liver Unit, Hospital Clinic, IDIBAPS and CIBERehd, University of Barcelona, Barcelona, Spain
| | - M C Londoño
- Liver Unit, Hospital Clinic, IDIBAPS and CIBERehd, University of Barcelona, Barcelona, Spain
| | - A Mira
- Department of Biochemistry and Molecular Genetics, Hospital Clinic, IDIBAPS and CIBERehd, University of Barcelona, Barcelona, Spain
| | - X Forns
- Liver Unit, Hospital Clinic, IDIBAPS and CIBERehd, University of Barcelona, Barcelona, Spain
| | - M Brunet
- Department of Biochemistry and Molecular Genetics, Hospital Clinic, IDIBAPS and CIBERehd, University of Barcelona, Barcelona, Spain
| | - W Jiménez
- Department of Biochemistry and Molecular Genetics, Hospital Clinic, IDIBAPS and CIBERehd, University of Barcelona, Barcelona, Spain
| | - M Navasa
- Liver Unit, Hospital Clinic, IDIBAPS and CIBERehd, University of Barcelona, Barcelona, Spain
| |
Collapse
|
16
|
Morata L, De la Calle C, Gómez-Cerquera JM, Manzanedo L, Casals G, Brunet M, Cobos-Trigueros N, Martínez JA, Mensa J, Soriano A. Risk factors associated with high linezolid trough plasma concentrations. Expert Opin Pharmacother 2016; 17:1183-7. [PMID: 27156708 DOI: 10.1080/14656566.2016.1182154] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
AIM The major concern of linezolid is the adverse events. High linezolid trough serum concentration (Cmin) has been associated with toxicity. The aim of this study was to analyze factors associated with high Cmin. METHODS Main clinical characteristics of 104 patients treated with 600 mg/12 hours of linezolid were retrospectively reviewed. Samples were obtained just before the next dose after at least three doses and within the first 8 days of treatment. High Cmin was considered when it was >8 mg/L. Univariate and multivariate analysis were performed. RESULTS 34.6% patients had a Cmin >8 mg/L, and they were older and had more frequently an estimated glomerular filtration by MDRD <40 mL/min. There were more patients co-treated with rifampin in the group with low Cmin. The only factor independently associated with Cmin >8 was the renal function. Patients with an eGF < 40 mL/min had significantly higher Cmin than those with eGF > 80 mL/min (OR: 4.273) and there was a trend towards a high Cmin in patients with eGF between 40-80 mL/min (OR: 2.109). CONCLUSIONS High Cmin were frequent, especially in patients with MDRD <40 mL/min. Therapeutic drug monitoring could be useful to avoid toxicity in patients with renal dysfunction.
Collapse
Affiliation(s)
- L Morata
- a Department of Infectious Diseases , Hospital Clínic of Barcelona , Barcelona , Spain
| | - C De la Calle
- a Department of Infectious Diseases , Hospital Clínic of Barcelona , Barcelona , Spain
| | - J M Gómez-Cerquera
- a Department of Infectious Diseases , Hospital Clínic of Barcelona , Barcelona , Spain
| | - L Manzanedo
- a Department of Infectious Diseases , Hospital Clínic of Barcelona , Barcelona , Spain
| | - G Casals
- b Department of Pharmacology and Toxicology , Hospital Clínic of Barcelona , Barcelona , Spain
| | - M Brunet
- b Department of Pharmacology and Toxicology , Hospital Clínic of Barcelona , Barcelona , Spain
| | - N Cobos-Trigueros
- a Department of Infectious Diseases , Hospital Clínic of Barcelona , Barcelona , Spain
| | - J A Martínez
- a Department of Infectious Diseases , Hospital Clínic of Barcelona , Barcelona , Spain
| | - J Mensa
- a Department of Infectious Diseases , Hospital Clínic of Barcelona , Barcelona , Spain
| | - A Soriano
- a Department of Infectious Diseases , Hospital Clínic of Barcelona , Barcelona , Spain
| |
Collapse
|
17
|
|
18
|
Boix F, Millan O, San Segundo D, Mancebo E, Miras M, Rimola A, Fábrega E, Allende L, Minguela A, Paz-Artal E, López-Hoyos M, Brunet M, Muro M. Activated Regulatory T Cells Expressing CD4+CD25highCD45RO+CD62L+ Biomarkers Could Be a Risk Factor in Liver Allograft Rejection. Transplant Proc 2015; 47:2380-1. [DOI: 10.1016/j.transproceed.2015.09.007] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
19
|
Cassier P, Bénet T, Nicolle MC, Brunet M, Buron F, Morelon E, Béraud L, Descours G, Jarraud S, Vanhems P. Community-acquired Legionnaires' disease in a renal transplant recipient with unclear incubation period: the importance of molecular typing. Transpl Infect Dis 2015; 17:756-60. [PMID: 26256573 DOI: 10.1111/tid.12432] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2015] [Revised: 07/13/2015] [Accepted: 07/26/2015] [Indexed: 11/29/2022]
Abstract
Transplant recipients are at risk of developing Legionnaires' disease (LD) because of impaired cellular immunity. Here, we describe a renal transplant recipient who developed LD at least 10 days after hospital admission and transplantation. The hospital water network was initially suspected, but further testing determined that the probable source was the patient's domestic water supply. Our report also suggests that the patient's immunosuppressed state may have switched potential colonization to pneumonia.
Collapse
Affiliation(s)
- P Cassier
- Hospices Civils de Lyon, Unité d'Hygiène et d'Epidémiologie, Groupement Hospitalier Edouard Herriot, Lyon, France.,Hospices Civils de Lyon, Centre National de Reference des Legionelles, Centre de Biologie Est Hospices Civils de Lyon, Bron, France.,CIRI, International Center for Infectiology Research, Legionella Pathogenesis Team, Université de Lyon, Lyon, France.,Inserm, U1111, Lyon, France.,Ecole Normale Supérieure de Lyon, Lyon, France.,Centre International de Recherche en Infectiologie, Université de Lyon 1, Lyon, France
| | - T Bénet
- Hospices Civils de Lyon, Unité d'Hygiène et d'Epidémiologie, Groupement Hospitalier Edouard Herriot, Lyon, France.,Laboratoire d'épidémiologie et de santé publique, CNRS, UMR5308, Université de Lyon 1, Lyon, France
| | - M C Nicolle
- Hospices Civils de Lyon, Unité d'Hygiène et d'Epidémiologie, Groupement Hospitalier Edouard Herriot, Lyon, France
| | - M Brunet
- Hospices Civils de Lyon, Transplantation, Néphrologie et Immunologie Clinique, Groupement Hospitalier Edouard Herriot, Lyon, France
| | - F Buron
- Hospices Civils de Lyon, Transplantation, Néphrologie et Immunologie Clinique, Groupement Hospitalier Edouard Herriot, Lyon, France
| | - E Morelon
- Hospices Civils de Lyon, Transplantation, Néphrologie et Immunologie Clinique, Groupement Hospitalier Edouard Herriot, Lyon, France
| | - L Béraud
- Hospices Civils de Lyon, Centre National de Reference des Legionelles, Centre de Biologie Est Hospices Civils de Lyon, Bron, France
| | - G Descours
- Hospices Civils de Lyon, Centre National de Reference des Legionelles, Centre de Biologie Est Hospices Civils de Lyon, Bron, France.,CIRI, International Center for Infectiology Research, Legionella Pathogenesis Team, Université de Lyon, Lyon, France.,Inserm, U1111, Lyon, France.,Ecole Normale Supérieure de Lyon, Lyon, France.,Centre International de Recherche en Infectiologie, Université de Lyon 1, Lyon, France
| | - S Jarraud
- Hospices Civils de Lyon, Centre National de Reference des Legionelles, Centre de Biologie Est Hospices Civils de Lyon, Bron, France.,CIRI, International Center for Infectiology Research, Legionella Pathogenesis Team, Université de Lyon, Lyon, France.,Inserm, U1111, Lyon, France.,Ecole Normale Supérieure de Lyon, Lyon, France.,Centre International de Recherche en Infectiologie, Université de Lyon 1, Lyon, France
| | - P Vanhems
- Hospices Civils de Lyon, Unité d'Hygiène et d'Epidémiologie, Groupement Hospitalier Edouard Herriot, Lyon, France.,Hospices Civils de Lyon, Centre National de Reference des Legionelles, Centre de Biologie Est Hospices Civils de Lyon, Bron, France.,CIRI, International Center for Infectiology Research, Legionella Pathogenesis Team, Université de Lyon, Lyon, France.,Inserm, U1111, Lyon, France.,Ecole Normale Supérieure de Lyon, Lyon, France.,Centre International de Recherche en Infectiologie, Université de Lyon 1, Lyon, France.,Laboratoire d'épidémiologie et de santé publique, CNRS, UMR5308, Université de Lyon 1, Lyon, France
| |
Collapse
|
20
|
Thévenet S, Mourad M, Bermudez E, Chanat C, Malin L, Alaaouch I, Casetta A, Poupet H, Brunet M, Chast F. PP-016 Validation of a new method of sterility testing for the vitamin and lipid mixtures destined for the neonatalogy department. Eur J Hosp Pharm 2015. [DOI: 10.1136/ejhpharm-2015-000639.296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
21
|
del Río A, Gasch O, Moreno A, Peña C, Cuquet J, Soy D, Mestres CA, Suárez C, Pare JC, Tubau F, Garcia de la Mària C, Marco F, Carratalà J, Gatell JM, Gudiol F, Miró JM, del Rio A, Moreno A, Pericas JM, Cervera C, Gatell JM, Marco F, de la Maria CG, Armero Y, Almela M, Mestres CA, Pare JC, Fuster D, Cartana R, Ninot S, Azqueta M, Sitges M, Heras M, Pomar JL, Ramirez J, Brunet M, Soy D, Llopis J, Gasch O, Suarez C, Pena C, Pujol M, Ariza J, Carratala J, Gudiol F, Cuquet J, Marti C, Mijana M. Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial. Clin Infect Dis 2014; 59:1105-12. [PMID: 25048851 DOI: 10.1093/cid/ciu580] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND There is an urgent need for alternative rescue therapies in invasive infections caused by methicillin-resistant Staphylococcus aureus (MRSA). We assessed the clinical efficacy and safety of the combination of fosfomycin and imipenem as rescue therapy for MRSA infective endocarditis and complicated bacteremia. METHODS The trial was conducted between 2001 and 2010 in 3 Spanish hospitals. Adult patients with complicated MRSA bacteremia or endocarditis requiring rescue therapy were eligible for the study. Treatment with fosfomycin (2 g/6 hours IV) plus imipenem (1 g/6 hours IV) was started and monitored. The primary efficacy endpoints were percentage of sterile blood cultures at 72 hours and clinical success rate assessed at the test-of-cure visit (45 days after the end of therapy). RESULTS The combination was administered in 12 patients with endocarditis, 2 with vascular graft infection, and 2 with complicated bacteremia. Therapy had previously failed with vancomycin in 9 patients, daptomycin in 2, and sequential antibiotics in 5. Blood cultures were negative 72 hours after the first dose of the combination in all cases. The success rate was 69%, and only 1 of 5 deaths was related to the MRSA infection. Although the combination was safe in most patients (94%), a patient with liver cirrhosis died of multiorgan failure secondary to sodium overload. There were no episodes of breakthrough bacteremia or relapse. CONCLUSIONS Fosfomycin plus imipenem was an effective and safe combination when used as rescue therapy for complicated MRSA bloodstream infections and deserves further clinical evaluation as initial therapy in these infections.
Collapse
Affiliation(s)
- Ana del Río
- Hospital Clínic-Institut d' Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona
| | - Oriol Gasch
- Hospital de Bellvitge-Institut d'Investigació Biomèdica de Bellvitge, University of Barcelona, L'Hospitalet de Llobregat Corporació Sanitària Parc Taulí, Universitat Autònoma de Barcelona, Sabadell
| | - Asunción Moreno
- Hospital Clínic-Institut d' Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona
| | - Carmen Peña
- Hospital de Bellvitge-Institut d'Investigació Biomèdica de Bellvitge, University of Barcelona, L'Hospitalet de Llobregat
| | - Jordi Cuquet
- Hospital General de Granollers, Universitat Internacional de Catalunya, Barcelona
| | - Dolors Soy
- Hospital Clínic-Institut d' Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona
| | - Carlos A Mestres
- Hospital Clínic-Institut d' Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona
| | - Cristina Suárez
- Hospital de Bellvitge-Institut d'Investigació Biomèdica de Bellvitge, University of Barcelona, L'Hospitalet de Llobregat
| | - Juan C Pare
- Hospital Clínic-Institut d' Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona
| | - Fe Tubau
- Hospital de Bellvitge-Institut d'Investigació Biomèdica de Bellvitge, University of Barcelona, L'Hospitalet de Llobregat CIBERES (CIBER de Enfermedades Respiratorias), ISCIII, Madrid
| | | | - Francesc Marco
- Hospital Clínic-Institut d' Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona Barcelona Centre for International Health Research (CRESIB, Hospital Clínic-Universitat de Barcelona), Spain
| | - Jordi Carratalà
- Hospital de Bellvitge-Institut d'Investigació Biomèdica de Bellvitge, University of Barcelona, L'Hospitalet de Llobregat
| | - José M Gatell
- Hospital Clínic-Institut d' Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona
| | - Francisco Gudiol
- Hospital de Bellvitge-Institut d'Investigació Biomèdica de Bellvitge, University of Barcelona, L'Hospitalet de Llobregat
| | - José M Miró
- Hospital Clínic-Institut d' Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Millán O, Rafael-Valdivia L, San Segundo D, Boix F, Castro-Panete M, López-Hoyos M, Muro M, Valero-Hervás D, Rimola A, Navasa M, Muñoz P, Miras M, Andrés A, Guirado L, Pascual J, Brunet M. Should IFN-γ, IL-17 and IL-2 be considered predictive biomarkers of acute rejection in liver and kidney transplant? Results of a multicentric study. Clin Immunol 2014; 154:141-54. [DOI: 10.1016/j.clim.2014.07.007] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2014] [Revised: 07/16/2014] [Accepted: 07/23/2014] [Indexed: 02/06/2023]
|
23
|
Gollion C, Brunet M, Fabre N, Larrue V, Viguier A, Bonneville F, Gollion C. Intérêt de la séquence coronale T2 dans le diagnostic d’hypotension intracrânienne débutante. Rev Neurol (Paris) 2014. [DOI: 10.1016/j.neurol.2014.01.137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
24
|
Brunet M, Gollion C, Tanchoux F, Kamsu J, Cognard C, Fabre N, Bonneville F. Intérêt de la séquence coronale T2 dans le diagnostic d’hypotension intracrânienne débutante. J Neuroradiol 2014. [DOI: 10.1016/j.neurad.2014.01.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
25
|
Dinh TM, Pech D, Brunet M, Achour A. High resolution electrochemical micro-capacitors based on oxidized multi-walled carbon nanotubes. ACTA ACUST UNITED AC 2013. [DOI: 10.1088/1742-6596/476/1/012106] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
26
|
Vignes S, Blanchard M, Brunet M, Arrault M, Lebrun-Vignes B. [Bullosis of the lower limb]. Rev Med Interne 2013; 35:403-4. [PMID: 24074970 DOI: 10.1016/j.revmed.2013.08.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2013] [Accepted: 08/21/2013] [Indexed: 10/26/2022]
Affiliation(s)
- S Vignes
- Unité de lymphologie, Centre national de référence des maladies vasculaires rares (lymphœdèmes primaires), hôpital Cognacq-Jay, 15, rue Eugène-Millon, 75015 Paris, France.
| | - M Blanchard
- Unité de lymphologie, Centre national de référence des maladies vasculaires rares (lymphœdèmes primaires), hôpital Cognacq-Jay, 15, rue Eugène-Millon, 75015 Paris, France
| | - M Brunet
- Unité de lymphologie, Centre national de référence des maladies vasculaires rares (lymphœdèmes primaires), hôpital Cognacq-Jay, 15, rue Eugène-Millon, 75015 Paris, France
| | - M Arrault
- Unité de lymphologie, Centre national de référence des maladies vasculaires rares (lymphœdèmes primaires), hôpital Cognacq-Jay, 15, rue Eugène-Millon, 75015 Paris, France
| | - B Lebrun-Vignes
- Service de pharmacologie, centre régional de pharmacovigilance, groupe hospitalier Pitié-Salpêtrière-Charles-Foix, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France
| |
Collapse
|
27
|
Farsi F, Klein I, Jovenin N, Labrosse H, Brunet M, Block V, Krakowski I. P312 A French Project Of Interregional And Shared Guidelines In Supportive Care. BMJ Qual Saf 2013. [DOI: 10.1136/bmjqs-2013-002293.252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
28
|
Vouillarmet J, Buron F, Houzard C, Carlier MC, Chauvet C, Brunet M, Thivolet C, Morelon E, Badet L. The first simultaneous kidney-adrenal gland-pancreas transplantation: outcome at 1 year. Am J Transplant 2013; 13:1905-9. [PMID: 23731324 DOI: 10.1111/ajt.12296] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2013] [Revised: 03/30/2013] [Accepted: 04/01/2013] [Indexed: 01/25/2023]
Abstract
Adrenal insufficiency is a rare but life-threatening disease. Replacement therapy sometimes fails to prevent an acute adrenal crisis and most often does not lead to restoration of well-being. We report here the 1-year outcome of the first simultaneous kidney-adrenal gland-pancreas transplantation in a 33-year-old patient with type 1 diabetes and concomitant autoimmune adrenal insufficiency. En bloc left adrenal gland and kidney grafts were anastomosed on the left iliac vessels in normal vascular conditions and the pancreas graft was anastomosed on the right iliac vessels. The immunosuppressive regimen was not modified by the addition of the adrenal gland. We observed no additional morbidity due to the adrenal gland transplantation, as there were no surgical complications. One-year kidney and pancreas graft functions were satisfactory (estimated glomerular filtration rate: 55 mL/min/1.73 m(2) and HbA1c: 4.8%). The adrenal graft functioned well at 12 months with a normalization of cortisol and aldosterone baseline levels. Functional imaging at 3 months showed good uptake of [(123) I]-metaiodobenzylguanidine by the adrenal graft. Transplantation of the adrenal gland en bloc with the left kidney appears to be a good therapeutic option in patients with adrenal insufficiency awaiting kidney or kidney-pancreas transplantation.
Collapse
Affiliation(s)
- J Vouillarmet
- Department of Endocrinology, Diabetes and Nutrition, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre Bénite, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Millán O, Rafael-Valdivia L, Torrademé E, López A, Fortuna V, Sánchez-Cabus S, López-Púa Y, Rimola A, Brunet M. Intracellular IFN-γ and IL-2 expression monitoring as surrogate markers of the risk of acute rejection and personal drug response in de novo liver transplant recipients. Cytokine 2012; 61:556-64. [PMID: 23265966 DOI: 10.1016/j.cyto.2012.10.026] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2012] [Revised: 10/26/2012] [Accepted: 10/27/2012] [Indexed: 01/09/2023]
Abstract
Biomarker monitoring is needed in transplantation to reflect individual response to immunosuppressive drugs and graft outcome. We evaluated intracellular expression and soluble production of interferon-(IFN)-γ and interleukin-(IL)-2 as predictive biomarkers of acute rejection (AR) and personal drug response. Pharmacokinetic-pharmacodynamic profiles were determined in 47 de novo liver recipients treated with tacrolimus, mycophenolate mofetil and prednisone. Of the 47 patients, AR occurred in nine. There were no differences in drug concentrations between rejectors and non-rejectors. A pre-transplantation cut-off value of 55.80% for %CD8(+)-IFN-γ(+) identified patients at high risk of AR with a sensitivity of 75% and a specificity of 82%. In the first week post-transplantation, patients with a % inhibition for soluble IFN-γ, %CD8(+)-IFN-γ(+) and %CD8(+)-IL2(+) lower than 40% developed AR, showing low susceptibility to immunosuppressive drugs. Therefore, effector-T-cell response monitoring may help physicians to identify personal response to treatment and patients at high risk of AR.
Collapse
Affiliation(s)
- O Millán
- Farmacología y Toxicología, Centro de Diagnóstico Biomédico, IDIBAPS, Hospital Clínico, Universidad de Barcelona, C/Villarroel 170, 08036 Barcelona, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
30
|
San Segundo D, Brunet M, Ballesteros M, Millán O, Muro M, Castro M, Miñambres E, López-Hoyos M. Prospective Study of Biomarkers of Immune Response in Lung Transplant Recipients. Transplant Proc 2012; 44:2666-8. [DOI: 10.1016/j.transproceed.2012.09.082] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
|
31
|
Chaintreuil D, Bénet T, Reverdy ME, Brunet M, Buron F, Chauvet C, Badet L, Vanhems P, Morelon E. Impact de la contamination du liquide de conservation sur les infections précoces des greffés rein-pancréas. Nephrol Ther 2012. [DOI: 10.1016/j.nephro.2012.07.086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
32
|
Brunet M. Cytokines as predictive biomarkers of alloreactivity. Clin Chim Acta 2012; 413:1354-8. [DOI: 10.1016/j.cca.2012.04.014] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2011] [Revised: 03/29/2012] [Accepted: 04/11/2012] [Indexed: 10/28/2022]
|
33
|
Buron F, Vouillarmet J, Brunet M, Chauvet C, Daoud S, Codas R, Carlier MC, Houzard C, Thivolet C, Morelon E, Badet L. Première transplantation simultanée rein – surrénale – pancréas : suivi à six mois. Nephrol Ther 2012. [DOI: 10.1016/j.nephro.2012.07.087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
34
|
Hanf W, Codas R, Meas-Yedid V, Berthiller J, Buron F, Chauvet C, Brunet M, Giroud A, McGregor BC, Olivo-Marin JC, Hadj-Aissa A, Faure A, Petruzzo P, Martin X, Badet L, Morelon E. Kidney graft outcome and quality (after transplantation) from uncontrolled deceased donors after cardiac arrest. Am J Transplant 2012; 12:1541-50. [PMID: 22390302 DOI: 10.1111/j.1600-6143.2011.03983.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
The use of uncontrolled deceased donors after cardiac arrest (uDDCA) has been developed in France to compensate for organ shortage. The quality of these kidneys remains unclear. We analyzed kidney graft function and histology from 27 uDDCA and compared them with kidneys from 30 extended criteria donors (ECD) and from 24 simultaneous pancreas kidney (SPK) donors as a control group of optimal deceased donors. Kidneys from ECD and SPK donors were preserved by static cold storage while kidneys from uDDCA were preserved by pulsatile perfusion. The uDDCA graft function at 3 years posttransplantation (estimated with MDRD and measured with inulin clearance) did not differ from that of the ECD group (eGFR 44.1 vs. 37.4 mL/min/1.73 m(2) , p = 0.13; mGFR 44.6 vs. 36.1 mL/min/1.73 m(2) , p = 0.07 in the uDDCA and ECD groups, respectively). The histological assessment of 3-month and 1-year protocol biopsies did not show differences for interstitial lesions between the uDDCA and ECD grafts (IF score at M3 was 30 vs. 28% and at M12 36 vs. 33%, p = NS). In conclusion, the results at 3 years with carefully selected and machine-perfused uDDCA kidneys have been comparable to ECD kidneys and encourage continuation of this program and development of similar programs.
Collapse
Affiliation(s)
- W Hanf
- Service de Néphrologie, Transplantation et Immunologie Clinique, Hôpital Edouard Herriot, Hospices Civils de Lyon, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Brunet M, Mosimann F. Education and imaging. Hepatobiliary and pancreatic: bile duct stricture after cholecystectomy. J Gastroenterol Hepatol 2011; 26:1466. [PMID: 21884253 DOI: 10.1111/j.1440-1746.2011.06841.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/09/2022]
Affiliation(s)
- M Brunet
- Surgery Division, Department of Surgery, Faculté de medicine et des sciences de la santé, Université de Sherbrooke, Sherbrooke (Québec), Canada
| | | |
Collapse
|
36
|
Rafael-Valdivia L, Mendoza MA, Martinez-Saldivar B, Sanchez-Fueyo A, Brunet M, Garcia-Valdecasas JC, Rimola A. How long should initiation of calcineurin inhibitors be delayed to protect renal function in liver transplantation? Transplant Proc 2011; 43:697-8. [PMID: 21486577 DOI: 10.1016/j.transproceed.2011.01.091] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
BACKGROUND AND AIM Delayed introduction of calcineurin inhibitors (CNI) in liver transplantation (OLT) seeks to protect renal function, although the optimal length of the delay is not well established. The aim of this study was to analyze the effects on renal function of CNI initiation on different days after OLT. METHODS We reviewed the charts of 260 OLT recipients. Group D1-a (n = 36) underwent the standard initial immunosuppression at our center: namely, CNI introduction on day 1 with further daily administration to achieve target levels of 8 to 15 ng/mL for tacrolimus or 150 to 300 ng/mL for cyclosporine. Due to renal concerns, 126 patients (group D1-b) had CNI introduced on day 1 either not daily or at doses to achieve less than the target on at least two occasions. In 43 patients (group D2), CNI were introduced on day 2 in 23 on day 3 (group D3), in 12 on day 4 (group D4), and at least at day 5 in 20 others (group D5). In periods without CNI treatment, patients received mycophenolate mofetil. Steroids were administered to all patients. The study period included the first 3 months post-OLT. Renal function was estimated as creatinine clearance (CrCl) using the Cockcroft-Gault equation. RESULTS Changes in CrCl from pre-OLT to month 3 were -19% ± 28% in group D1-a; -27% ± 19% in group D1-b; -29% ± 19% in group D2; -23% ± 26% in group D3; -4% ± 38% in group D4, and +4% ± 33% in group D5 (P < .05 vs groups D1-a, D1-b, D2, and D3). On multivariate analysis, CNI introduction at day ≥ 5 was protective for kidneys when adjusted for other variables that potentially influence renal function. CONCLUSION CNI should be introduced at day 5 after OLT to protect renal function.
Collapse
|
37
|
Guillén D, Millán O, Brunet M. In Vitro Studies of the Immunomodulatory Effects of Statins Alone and in Combination with Immunosuppressive Drugs. EUR J INFLAMM 2011. [DOI: 10.1177/1721727x1100900205] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
The effects of statins go beyond their lipid-lowering properties and include immunomodulatory and anti-inflammatory effects. Unfortunately, there is a lack of in vitro assays that study the immunomodulatory effect of statins at therapeutic concentrations and the possible synergism with immunosuppressive drugs. Besides, they are mostly evaluated on isolated peripheral blood mononuclear cells instead of using whole blood as a matrix. The aim of this study is to perform in vitro experiments to evaluate the effect of atorvastatin, simvastatin and fluvastatin at therapeutic concentrations alone and in combination with everolimus or tacrolimus on immunosuppressive response, using whole blood as a matrix by investigating lymphocyte proliferation and production of the soluble cytokines interleukin (IL)-2, IL-10 and interferon (IFN)-γ. Statins (0.1 μM) inhibited T cell proliferation by 12–16% in a dose-dependent manner and when statins at 0.1 μM were combined with each immunosuppressive drug at 8 ng/ml, inhibition increased by 6–9% (p<0.05) for everolimus and 8–15% (p<0.05) for tacrolimus, but not for atorvastatin. At a dose of 0.1 μM, all three statins inhibited soluble IFN-γ production by approximately 5–9% (p<0.02). IL-2 and IL-10 production were unaltered by the presence of statins. These findings suggest that statins seem to exert a mild anti-inflammatory effect that might potentially be used to treat autoimmune diseases.
Collapse
Affiliation(s)
- D. Guillén
- Pharmacology and Toxicology Laboratory (CDB), IDIBAPS, Hospital Clinic of Barcelona, Barcelona
- Departament de Salut Pública, Facilitat de Medicina, Barcelona University, Barcelona, Spain
| | - O. Millán
- Pharmacology and Toxicology Laboratory (CDB), IDIBAPS, Hospital Clinic of Barcelona, Barcelona
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona
| | - M. Brunet
- Pharmacology and Toxicology Laboratory (CDB), IDIBAPS, Hospital Clinic of Barcelona, Barcelona
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona
- Departament de Salut Pública, Facilitat de Medicina, Barcelona University, Barcelona, Spain
| |
Collapse
|
38
|
Petruzzo P, Kanitakis J, Badet L, Pialat JB, Boutroy S, Charpulat R, Mouly J, Gazarian A, Lanzetta M, Brunet M, Devauchelle B, Testelin S, Martin X, Dubernard JM, Morelon E. Long-term follow-up in composite tissue allotransplantation: in-depth study of five (hand and face) recipients. Am J Transplant 2011; 11:808-16. [PMID: 21446980 DOI: 10.1111/j.1600-6143.2011.03469.x] [Citation(s) in RCA: 92] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Composite tissue allotransplantations (CTAs) have clinically shown little, if any, evidence of chronic rejection. Consequently, the effect of chronic rejection on bones, joints, nerves, muscles, tendons and vessels may still have undescribed implications. We thoroughly assessed all allograft structures by histology, magnetic resonance imaging, ultrasonography and high resolution peripheral quantitative computed tomography scan in four bilateral hand-grafted patients (10, 7, 3 and 2 years of follow-up, respectively) and in one facial allotransplantation (5 years of follow-up). All the recipients presented normal skin structure without dermal fibrosis. Vessels were patent, without thrombosis, stenosis or intimal hyperplasia. Tendons and nerves were also normal; muscles showed some changes, such as a variable degree of muscular hypotrophy, particularly of intrinsic muscles, accompanied by fatty degeneration that might be related to denervation. In the majority of hand-grafted patients graft radius and recipient tibia showed a decrease in trabecular density, although in the graft radius the alterations also involved the cortices. No deterioration of graft function was noted. In these cases of CTA no signs of chronic graft rejection have been detected. However, the possibility that chronic rejection may develop in CTA exists, highlighting the necessity of close continuous follow-up of the patients.
Collapse
Affiliation(s)
- P Petruzzo
- Department of Transplantation, Hopital Edouard Herriot, Lyon, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Brunet M, Martorell J, Oppenheimer F, Vilardell J, Millán O, Carrillo M, Rojo I, Corbella J. Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil. Transpl Int 2011. [DOI: 10.1111/j.1432-2277.2000.tb02045.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
40
|
Gallego MC, Trigo RM, Vaquero JM, Brunet M, García JA, Sigró J, Valente MA. Trends in frequency indices of daily precipitation over the Iberian Peninsula during the last century. ACTA ACUST UNITED AC 2011. [DOI: 10.1029/2010jd014255] [Citation(s) in RCA: 72] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
41
|
Bellon N, Maigné G, Anguel N, Brunet M, Goujard C, Lambotte O. Association chondrite auriculaire et microangiopathie thrombotique : mode de début inhabituel pour un lupus érythémateux disséminé. Rev Med Interne 2010. [DOI: 10.1016/j.revmed.2010.03.253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
42
|
Abstract
Cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells are indispensable factors in the body's ongoing defence against viral infection and tumor development. CTL/NK cells recognize and kill infected or aberrant target cells by two major pathways: either through introduction of a battery of proteases - called granzymes - to the target cell cytosol, or through TNF superfamily-dependent killing. During granzyme-dependent killing, target cell death is quick and efficient and is mediated by multiple granzymes, acting via redundant cell death pathways. Although granzyme-mediated cell death has been intensively studied, recent work has also hinted at an alternative, proinflammatory role for these enzymes. Thus, in addition to their well-established role as intracellular effectors of target cell death, recent data suggest that granzymes may have an extracellular role in the propagation of immune signals. In this study, we discuss the role of granzymes as central factors in antitumor immunity, as well possible roles for these proteases as instigators of inflammation.
Collapse
Affiliation(s)
- S P Cullen
- Department of Genetics, Molecular Cell Biology Laboratory, The Smurfit Institute, Trinity College, Dublin D2, Ireland
| | | | | |
Collapse
|
43
|
Bigorgne L, Brunet M, Maigre H. Wood transverse fracture analysis at the mesoscopic scale. EPJ Web of Conferences 2010. [DOI: 10.1051/epjconf/20100628006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
44
|
Aguilar E, Aziz Barry A, Brunet M, Ekang L, Fernandes A, Massoukina M, Mbah J, Mhanda A, do Nascimento DJ, Peterson TC, Thamba Umba O, Tomou M, Zhang X. Changes in temperature and precipitation extremes in western central Africa, Guinea Conakry, and Zimbabwe, 1955–2006. ACTA ACUST UNITED AC 2009. [DOI: 10.1029/2008jd011010] [Citation(s) in RCA: 202] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
45
|
Abstract
Many different external and intrinsic apoptotic stimuli induce the accumulation in the cells of a set of proteins known as stress or heat shock proteins (HSPs). HSPs are conserved proteins present in both prokaryotes and eukaryotes. These proteins play an essential role as molecular chaperones by assisting the correct folding of nascent and stress-accumulated misfolded proteins, and by preventing their aggregation. HSPs have a protective function, that is they allow the cells to survive to otherwise lethal conditions. Various mechanisms have been proposed to account for the cytoprotective functions of HSPs. Several of these proteins have demonstrated to directly interact with components of the cell signalling pathways, for example those of the tightly regulated caspasedependent programmed cell death machinery, upstream, downstream and at the mitochondrial level. HSPs can also affect caspase-independent apoptosis-like process by interacting with apoptogenic factors such as apoptosis-inducing factor (AIF) or by acting at the lysosome level. This review will describe the different key apoptotic proteins interacting with HSPs and the consequences of these interactions in cell survival, proliferation and apoptotic processes. Our purpose will be illustrated by emerging strategies in targeting these protective proteins to treat haematological malignancies.
Collapse
|
46
|
Didelot C, Lanneau D, Brunet M, Bouchot A, Cartier J, Jacquel A, Ducoroy P, Cathelin S, Decologne N, Chiosis G, Dubrez-Daloz L, Solary E, Garrido C. Interaction of heat-shock protein 90β isoform (HSP90β) with cellular inhibitor of apoptosis 1 (c-IAP1) is required for cell differentiation. Cell Death Differ 2008:4402320. [PMID: 25361076 DOI: 10.1038/sj.cdd.4402320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2007] [Revised: 11/22/2007] [Accepted: 12/09/2007] [Indexed: 11/09/2022] Open
Abstract
Members of the inhibitor of apoptosis protein (IAP) family have demonstrated functions in cell death, cell signalling, cell migration and mitosis. Several of them are E3 enzymes in the ubiquitination of proteins that leads to their degradation by the proteosomal machinery. We previously reported that one of them, cellular inhibitor of apoptosis protein-1 (c-IAP1), migrated from the nucleus to the surface of the Golgi apparatus in cells undergoing differentiation. Here, we show that c-IAP1 is a client protein of the stress protein HSP90β. In three distinct cellular models, the two proteins interact and migrate from the nucleus to the cytoplasm along the differentiation process through a leptomycin B-sensitive pathway. Inhibition of HSP90 proteins by small chemical molecules and specific depletion of HSP90β isoform by siRNA both lead to auto-ubiquitination of c-IAP1 and its degradation by the proteasome machinery. This chaperone function of HSP90 towards c-IAP1 is specific of its β isoform as specific depletion of HSP90α does not affect c-IAP1 content. Chemical inhibition of HSP90 or siRNA-mediated depletion of HSP90β both inhibit cell differentiation, which can be reproduced by siRNA-mediated depletion of c-IAP1. Altogether, these results suggest that HSP90β prevents auto-ubiquitination and degradation of its client protein c-IAP1, whose depletion would be sufficient to inhibit cell differentiation.Cell Death and Differentiation advance online publication, 1 February 2008; doi:10.1038/sj.cdd.4402320.
Collapse
Affiliation(s)
- C Didelot
- 1] INSERM, UMR 866, Dijon, France [2] University of Burgundy, Dijon, France
| | - D Lanneau
- 1] INSERM, UMR 866, Dijon, France [2] University of Burgundy, Dijon, France
| | - M Brunet
- 1] INSERM, UMR 866, Dijon, France [2] University of Burgundy, Dijon, France
| | | | | | | | - P Ducoroy
- 1] IFR-Sante-STIC, Dijon, France [2] Department of haematology, CHU Le Bocage, Dijon, France
| | - S Cathelin
- 1] INSERM, UMR 866, Dijon, France [2] University of Burgundy, Dijon, France
| | - N Decologne
- 1] INSERM, UMR 866, Dijon, France [2] University of Burgundy, Dijon, France
| | - G Chiosis
- Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | - L Dubrez-Daloz
- 1] INSERM, UMR 866, Dijon, France [2] University of Burgundy, Dijon, France
| | - E Solary
- 1] INSERM, UMR 866, Dijon, France [2] University of Burgundy, Dijon, France
| | - C Garrido
- 1] INSERM, UMR 866, Dijon, France [2] University of Burgundy, Dijon, France
| |
Collapse
|
47
|
Brunet M, Crespo M, Millán O, Serón D, Torregrosa V, Jiménez O, Moreso F, Martorell J, Grinyo JM, Oppenheimer F. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic. Transplant Proc 2007; 39:2160-2. [PMID: 17889124 DOI: 10.1016/j.transproceed.2007.07.003] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
INTRODUCTION Efficacious prophylaxis of acute rejection episodes (ARE) requires adequate exposure to each component of the immunosuppressive treatment from the first days after renal transplantation. The aim of the present study was to evaluate the correlation between cyclosporine (CsA) and mycophenolic acid (MPA) exposure based upon pharmacokinetics (PK) and pharmacodynamics (PD) and 6-month biopsy-proven acute rejection (BPAR) episodes and chronic allograft nephropathy on 6 month protocol biopsies. PATIENTS AND METHODS We examined twenty-two first or second de novo renal transplant recipients treated with steroids, Sandimmune Neoral (CsA) and Myfortic (720 mg twice a day). PK (C0, C2, and AUC(0-12h)) for both drugs were determined on days 7, 90, and 180. Calcineurin activity, interleukin-2 and interferon-gamma synthesis as well as %CEM were tested at days 7 and 180. CsA dosages were adjusted by C2 monitoring. Collected data included: BPAR during the first 6 months and Banff histological parameters on the 6-month protocol biopsies. RESULTS Eighteen of 22 patients completed 1 year follow-up under treatment. The 6-month BPAR was 18% (4/22). Six-month protocol biopsies in 50% of 14 recipients showed chronic allograft nephropathy 1. At day 7, CsA C2 and AUC median values were 138 ng/mL and 6377 ng x h/mL, while C0 MPA was 1.0 microg/mL and AUC = 23.9 microg x h/mL. CsA C2 medians at 3 and 6 months were 1468 and 1720 ng/mL. MPA-AUC reached therapeutic targets at 3 months (32.3 microg x h/mL) and was 48.3 microg x h/mL at 6 months. Patients with BPAR showed lower CsA AUC (P = .06) and a significantly lower baseline inhibition of calcineurin activity (P < .005) than patients with no BPAR. An increase in mesangial matrix in 6-month protocol biopsies correlated with higher CsA C2 (P = .01). All biomarkers evaluated were significantly inhibited compared with the standard population. CONCLUSIONS When Myfortic is administered together with CsA, it is advisable to begin with higher doses (720 mg x 3 days) to reach adequate PK targets and improve BPAR rates. To prevent chronic allograft nephropathy, lower CsA C2 should be targeted from 3 months.
Collapse
Affiliation(s)
- M Brunet
- Pharmacology Department (CDB), Hospital Clinic Barcelona, Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Meier JG, Nobili M, Carlsson T, Rudquist P, Petrenko AS, Goodby JW, Brunet M, Lagerwall ST. Possible model of an antiferroelectric twist grain boundary phase. Phys Rev E Stat Nonlin Soft Matter Phys 2007; 76:011704. [PMID: 17677468 DOI: 10.1103/physreve.76.011704] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/04/2006] [Indexed: 05/16/2023]
Abstract
Using x-ray and optical methods we have probed the structural organization of an antiferroelectric twist grain boundary phase (TGBC(a)) lying between the regular antiferroelectric smectic-C (SmC(a)* and the smectic-Q (SmQ) or isotropic phase. We find that the twist axis is everywhere perpendicular to the local smectic layer normal and that the helical superstructure is incommensurate with the smectic layer structure. The twist grain boundaries consist of a periodic lattice of alternating +1/2 and -1/2 dispirations, i.e., unit screw dislocations in combination with half unit disclinations. The molecular tilt plane is alternatingly parallel and perpendicular to the twist axis. We find that the optically measured tilt angle in the SmC(a)* phase is smaller than that measured by x rays, which is the opposite to what is found in the SmC* phase. This means that the core part tilts less than the end chains in the SmC(a)* phase, while it tilts more in the SmC* phase. On entering the TGB phase a clear decrease is measured in the tilt angle. This is explained by the elastic influence from the disclinations, which appear in this phase.
Collapse
Affiliation(s)
- J G Meier
- Department of Microelectronics and Nanoscience, Chalmers University of Technology, S-41296 Göteborg, Sweden
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Brunet M, Jones PD, Sigró J, Saladié O, Aguilar E, Moberg A, Della-Marta PM, Lister D, Walther A, López D. Temporal and spatial temperature variability and change over Spain during 1850–2005. ACTA ACUST UNITED AC 2007. [DOI: 10.1029/2006jd008249] [Citation(s) in RCA: 164] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
50
|
Houssameddine D, Ebels U, Delaët B, Rodmacq B, Firastrau I, Ponthenier F, Brunet M, Thirion C, Michel JP, Prejbeanu-Buda L, Cyrille MC, Redon O, Dieny B. Spin-torque oscillator using a perpendicular polarizer and a planar free layer. Nat Mater 2007; 6:441-7. [PMID: 17468761 DOI: 10.1038/nmat1905] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/05/2006] [Accepted: 04/05/2007] [Indexed: 05/15/2023]
Abstract
Spintronics materials have recently been considered for radio-frequency devices such as oscillators by exploiting the transfer of spin angular momentum between a spin-polarized electrical current and the magnetic nanostructure it passes through. While previous spin-transfer oscillators (STOs) were based on in-plane magnetized structures, here we present the realization of an STO that contains a perpendicular spin current polarizer combined with an in-plane magnetized free layer. This device is characterized by high-frequency oscillations of the free-layer magnetization, consistent with out-of-plane steady-state precessions induced at the threshold current by a spin-transfer torque from perpendicularly polarized electrons. The results are summarized in static and dynamic current-field state diagrams and will be of importance for the design of STOs with enhanced output signals.
Collapse
Affiliation(s)
- D Houssameddine
- SPINTEC URA 2512, C.E.A/DRFMC-CNRS, Commissariat á l'Energie Atomique-Grenoble, 17 rue des Martyrs, 38054 Grenoble, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|